Solriamfetol in Binge Eating Disorder
Status unconfirmed · Phase 4 · Has a placebo group
Conditions studied: Binge Eating Disorder
In brief
The goal of this project is to evaluate the efficacy and tolerability of the novel dopamine and norepinephrine reuptake inhibitor (DNRI) solriamfetol in the treatment of binge eating disorder (BED).
Key facts
- Study ID
- NCT04602936
- Run by
- Lindner Center of HOPE
- People needed
- 64
- Starts
- 2021-06-15
- Expected to finish
- 2024-12-30
- Last updated by the study team
- 2023-03-08
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Lindner Center of HOPE — Mason, Ohio, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.